



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company
CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2023-24

1st July, 2023

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Sub: Pursuant to the Regulation 30 of SEBI (LODR) Regulations, 2015 for Capacity addition/Expansion.

Dear Sir/Ma'am,

This has in reference to our letter no. SYNCOM/SE/2023-24, SYNCOM/SE/2020-21 and SYNCOM/SE/2022-23 dated 29th May, 2023, 18th December, 2020 and 15th September, 2022 respectively for notice under Regulation 30 of SEBI (LODR) Regulations, 2015 by which it was informed that our project for expansion cum Modernization of the Company's existing plant 256-257, Industrial Area Sector I Pithampur, District Dhar (M.P.) 454775.

The Company announces further that *Trial Production* is started from 30th June, 2023. Subsequent to that *Commercial Production* may start by end of August, 2023 subject to successful Trial Run.


The company will host other updates related to expansion cum modernization on the event of its occurrence.

We request you to please take the above information on your record.

Thanking you,
Yours faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

KEDARMAL SHANKARLAL BANKDA
CHAIRMAN AND WHOLE-TIME DIRECTOR
DIN- 00023050



Bringing a smile on every face...